Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination

Severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) has emerged as the infectious agent causing the pandemic coronavirus disease 2019 (COVID-19) with dramatic consequences for global human health and economics. Previously, we reached clinical evaluation with our vector vaccine based...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Proc Natl Acad Sci U S A
Main Authors: Tscherne, Alina, Schwarz, Jan Hendrik, Rohde, Cornelius, Kupke, Alexandra, Kalodimou, Georgia, Limpinsel, Leonard, Okba, Nisreen M. A., Bošnjak, Berislav, Sandrock, Inga, Odak, Ivan, Halwe, Sandro, Sauerhering, Lucie, Brosinski, Katrin, Liangliang, Nan, Duell, Elke, Jany, Sylvia, Freudenstein, Astrid, Schmidt, Jörg, Werner, Anke, Gellhorn Serra, Michelle, Klüver, Michael, Guggemos, Wolfgang, Seilmaier, Michael, Wendtner, Clemens-Martin, Förster, Reinhold, Haagmans, Bart L., Becker, Stephan, Sutter, Gerd, Volz, Asisa
Formato: Artigo
Idioma:Inglês
Publicado em: National Academy of Sciences 2021
Assuntos:
Biological Sciences
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8285915/
https://ncbi.nlm.nih.gov/pubmed/34162739
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.2026207118
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados